Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

StemCyte

StemCyte
1997 FOUNDED
PRIVATE STATUS
201-300 EMPLOYEES
Later Stage VC LATEST DEAL TYPE
9 INVESTORS
Description

Developer of regenerative cell therapy (RCT) technologies, focusing on stem cell transplantation and regenerative medicine by using a proprietary platform mononuclear cell (MNC) technology derived from its large and genetically diverse donor cord blood stem cell bank. The company's proprietary platform MNC technology aims to apply the treatment to neurologic diseases such as Spinal Cord Injury, Stroke, Parkinson's Disease, Macular Degeneration and Alzheimer's disease.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Other Industries
Biotechnology
Other Devices and Supplies
Primary Office
  • 13800 Live Oak Avenue
  • Baldwin Park, CA 91706
  • United States

+1 (626) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore StemCyte’s full profile, request a free trial.

StemCyte Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Later Stage VC 000.00 Completed Generating Revenue
9. Secondary Transaction - Private 000.00 Completed Generating Revenue
8. Debt - General 23-Nov-2010 000.00 Completed Generating Revenue
7. Debt - General 01-Jun-2009 000 000.00 Completed Generating Revenue
6. Convertible Debt 02-Oct-2007 00.000 000.00 Completed Generating Revenue
5. Later Stage VC (Series 3) 14-Jul-2006 00.00 000.00 Completed Generating Revenue
4. Later Stage VC (Series D) 20-May-2002 00.000 000.00 0000 Completed Startup
3. Later Stage VC (Series C) 14-Feb-2002 00.00 000.00 00000 Completed Startup
2. Early Stage VC (Series B) 02-Oct-2000 $5.46M $5.46M 000.00 Completed Startup
1. Early Stage VC (Series A) Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

StemCyte Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series D 0,000,000 00.000000 00 00.0 00.0 00 00.0 00.000
Series C 000,000 00.000000 00 000 000 00 00.00 0.000
Series B 1,821,000 $0.001000 7% $3 $3 1x $2.5 11.51%
Series A 1,850,000 $0.001000 7% $2.5 $2.5 1x $1 24.36%
To view this company’s complete Cap Table, request access »

StemCyte Competitors (1)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
00000000 000000000 Venture Capital-Backed Chennai, India 0000 00.00 0000000000 0 00.00
To view this company’s complete list of competitors, request access »

StemCyte Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Amkey Ventures Venture Capital Minority 000 0000 000000 0
Fairbridge Venture Partners Venture Capital Minority 000 0000 000000 0
Kenson Ventures Venture Capital Minority 000 0000 000000 0
Kuwait Life Sciences Company Venture Capital Minority 000 0000 000000 0
Montage Capital Mezzanine Minority 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »

StemCyte Executive Team (8)

Name Title Board
Seat
Contact
Info
Jonas Wang Ph.D Chief Executive Officer, President & Chairman
Deepak Chhabra Chief Executive Officer, India
Charles Lu Chief Operating Officer
Kenneth Giacin Vice Chairman & Chief Strategy Officer
Wise Young Ph.D Chief Science and Medical Advisor

2 Former Executives

You’re viewing 5 of 8 executives. Get the full list »

StemCyte Board Members (7)

Name Representing Role Since Contact
Info
George Lee Ph.D Amkey Ventures Board Member 000 0000
Jonas Wang Ph.D StemCyte Chief Executive Officer, President & Chairman 000 0000
Kenneth Giacin StemCyte Vice Chairman & Chief Strategy Officer 000 0000
Lawrence Petz MD StemCyte Chief Medical Officer & Chairman of Medical Advisory Board 000 0000
MeiAnn Liu Self Board Member 000 0000

2 Former Board Members

You’re viewing 5 of 7 board members. Get the full list »